ACE2 and a Traditional Chinese Medicine Formula NRICM101 Could Alleviate the Inflammation and Pathogenic Process of Acute Lung Injury
Abstract
:1. Introduction
2. Materials and Methods
2.1. Cell Line and Cell Culture
2.2. Acid and NRICM101 Treatment of Cells
2.3. Determination of Cell Viability
2.4. Determination of ROS Production
2.5. Animal Model
2.6. Acid and NRICM101 Treatment of Animals
2.7. Lung Histopathology
2.8. Enzyme-Linked Immunosorbent Assay (ELISA)
2.9. Western Blotting
2.10. Gelatin Zymography
2.11. Statistical Analysis
3. Results
3.1. NRICM101 Promoted Viability and Reduced Oxidative Stress in Acid-Treated A549 Cells
3.2. ACE2 and NRICM101 Enhanced Vitality in Mice with Acid-Induced ALI
3.3. ACE2 and NRICM101 Reversed Histopathological Changes in ALI Mice
3.4. ACE2 and NRICM101 Ameliorated Pulmonary Inflammation in ALI Mice
3.5. NRICM101 Administration Countered the Imbalance in ACE in ALI Mice
3.6. ACE2 and NRICM101 Alleviated STAT3 and ERK1/2 Phosphorylation in the Lungs of ALI Mice
3.7. ACE2 and NRICM101 Modulated Pulmonary Gelatinase Activity in Mice with Acid-Induced ALI
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Fleming, I.; Kohlstedt, K.; Busse, R. The tissue renin-angiotensin system and intracellular signalling. Curr. Opin. Nephrol. Hypertens. 2006, 15, 8–13. [Google Scholar] [CrossRef] [PubMed]
- Imai, Y.; Kuba, K.; Ohto-Nakanishi, T.; Penninger, J.M. Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ. J. 2010, 74, 405–410. [Google Scholar] [CrossRef]
- Corvol, P.; Williams, T.A.; Soubrier, F. Peptidyl dipeptidase A: Angiotensin I-converting enzyme. Methods Enzymol. 1995, 248, 283–305. [Google Scholar] [CrossRef]
- Vickers, C.; Hales, P.; Kaushik, V.; Dick, L.; Gavin, J.; Tang, J.; Godbout, K.; Parsons, T.; Baronas, E.; Hsieh, F.; et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 2002, 277, 14838–14843. [Google Scholar] [CrossRef]
- Donoghue, M.; Hsieh, F.; Baronas, E.; Godbout, K.; Gosselin, M.; Stagliano, N.; Donovan, M.; Woolf, B.; Robison, K.; Jeyaseelan, R.; et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 2000, 87, E1–E9. [Google Scholar] [CrossRef] [PubMed]
- Tipnis, S.R.; Hooper, N.M.; Hyde, R.; Karran, E.; Christie, G.; Turner, A.J. A human homolog of angiotensin-converting enzyme: Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 2000, 275, 33238–33243. [Google Scholar] [CrossRef]
- Mizuiri, S.; Ohashi, Y. ACE and ACE2 in kidney disease. World J. Nephrol. 2015, 4, 74–82. [Google Scholar] [CrossRef]
- Soler, M.J.; Batlle, M.; Riera, M.; Campos, B.; Ortiz-Perez, J.T.; Anguiano, L.; Roca-Ho, H.; Farrero, M.; Mont, L.; Pascual, J.; et al. ACE2 and ACE in acute and chronic rejection after human heart transplantation. Int. J. Cardiol. 2019, 275, 59–64. [Google Scholar] [CrossRef]
- Zamai, L. The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients. Cells 2020, 9, 1704. [Google Scholar] [CrossRef] [PubMed]
- Santos, R.A.; e Silva, A.C.S.; Maric, C.; Silva, D.M.; Machado, R.P.; de Buhr, I.; Heringer-Walther, S.; Pinheiro, S.V.B.; Lopes, M.T.; Bader, M. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. USA 2003, 100, 8258–8263. [Google Scholar] [CrossRef]
- Mercure, C.; Yogi, A.; Callera, G.E.; Aranha, A.B.; Bader, M.; Ferreira, A.J.; Santos, R.A.; Walther, T.; Touyz, R.M.; Reudelhuber, T.L. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ. Res. 2008, 103, 1319–1326. [Google Scholar] [CrossRef] [PubMed]
- Zhou, P.; Yang, X.L.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.R.; Zhu, Y.; Li, B.; Huang, C.L.; et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020, 579, 270–273. [Google Scholar] [CrossRef] [PubMed]
- He, M.; Zhang, S.; Su, Q.; Liu, D.; Li, G.; Xiang, Q.; Sun, Y.; Luo, Y.; Li, T.; Wu, Y. Global Infectious Diseases in January 2023: Monthly Analysis. Zoonoses 2023, 3, 17. [Google Scholar] [CrossRef]
- Wilhelm, E.; Ballalai, I.; Belanger, M.-E.; Benjamin, P.; Bertrand-Ferrandis, C.; Bezbaruah, S.; Briand, S.; Brooks, I.; Bruns, R.; Bucci, L.M. Measuring the burden of infodemics: Summary of the methods and results of the Fifth WHO Infodemic Management Conference. JMIR Infodemiol. 2023, 3, e44207. [Google Scholar] [CrossRef]
- Ni, W.; Yang, X.; Yang, D.; Bao, J.; Li, R.; Xiao, Y.; Hou, C.; Wang, H.; Liu, J.; Yang, D.; et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit. Care 2020, 24, 422. [Google Scholar] [CrossRef]
- Banu, N.; Panikar, S.S.; Leal, L.R.; Leal, A.R. Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications. Life Sci. 2020, 256, 117905. [Google Scholar] [CrossRef] [PubMed]
- South, A.M.; Diz, D.I.; Chappell, M.C. COVID-19, ACE2, and the cardiovascular consequences. Am. J. Physiol. Heart Circ. Physiol. 2020, 318, H1084–H1090. [Google Scholar] [CrossRef] [PubMed]
- Garcia, G.E.; Truong, L.D.; Johnson, R.J. Angiotensin-converting enzyme 2 decreased expression during kidney inflammatory diseases: Implications to predisposing to COVID-19 kidney complications. Kidney Int. 2021, 100, 1138–1140. [Google Scholar] [CrossRef]
- Yan, R.; Zhang, Y.; Li, Y.; Xia, L.; Guo, Y.; Zhou, Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020, 367, 1444–1448. [Google Scholar] [CrossRef]
- Rockx, B.; Baas, T.; Zornetzer, G.A.; Haagmans, B.; Sheahan, T.; Frieman, M.; Dyer, M.D.; Teal, T.H.; Proll, S.; van den Brand, J.; et al. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J. Virol. 2009, 83, 7062–7074. [Google Scholar] [CrossRef]
- Klein, N.; Gembardt, F.; Supe, S.; Kaestle, S.M.; Nickles, H.; Erfinanda, L.; Lei, X.; Yin, J.; Wang, L.; Mertens, M.; et al. Angiotensin-(1-7) protects from experimental acute lung injury. Crit. Care Med. 2013, 41, e334–e343. [Google Scholar] [CrossRef] [PubMed]
- South, A.M.; Tomlinson, L.; Edmonston, D.; Hiremath, S.; Sparks, M.A. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat. Rev. Nephrol. 2020, 16, 305–307. [Google Scholar] [CrossRef] [PubMed]
- Wang, K.; Gheblawi, M.; Oudit, G.Y. Angiotensin Converting Enzyme 2: A Double-Edged Sword. Circulation 2020, 142, 426–428. [Google Scholar] [CrossRef]
- Yan, T.; Xiao, R.; Lin, G. Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword? FASEB J. 2020, 34, 6017–6026. [Google Scholar] [CrossRef] [PubMed]
- Centers for Disease Control and Prevention. Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19); WHO: Geneva, Switzerland, 2021.
- Muñoz-Fontela, C.; Dowling, W.E.; Funnell, S.G.; Gsell, P.-S.; Riveros-Balta, A.X.; Albrecht, R.A.; Andersen, H.; Baric, R.S.; Carroll, M.W.; Cavaleri, M. Animal models for COVID-19. Nature 2020, 586, 509–515. [Google Scholar] [CrossRef] [PubMed]
- Johansen, M.; Irving, A.; Montagutelli, X.; Tate, M.; Rudloff, I.; Nold, M.; Hansbro, N.; Kim, R.; Donovan, C.; Liu, G. Animal and translational models of SARS-CoV-2 infection and COVID-19. Mucosal Immunol. 2020, 13, 877–891. [Google Scholar] [CrossRef] [PubMed]
- Swenson, K.E.; Swenson, E.R. Pathophysiology of Acute Respiratory Distress Syndrome and COVID-19 Lung Injury. Crit. Care Clin. 2021, 37, 749–776. [Google Scholar] [CrossRef] [PubMed]
- Hu, B.; Huang, S.; Yin, L. The cytokine storm and COVID-19. J. Med. Virol. 2021, 93, 250–256. [Google Scholar] [CrossRef] [PubMed]
- Yang, Y.; Islam, M.S.; Wang, J.; Li, Y.; Chen, X. Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective. Int. J. Biol. Sci. 2020, 16, 1708–1717. [Google Scholar] [CrossRef]
- Ge, R. Targeting airway macrophages for inflammatory lung diseases-insights from traditional Chinese medicine. Ann. Transl. Med. 2022, 10, 1086. [Google Scholar] [CrossRef]
- Zhao, J.; Yang, Y.; Huang, H.; Li, D.; Gu, D.; Lu, X.; Zhang, Z.; Liu, L.; Liu, T.; Liu, Y. Relationship between the ABO blood group and the coronavirus disease 2019 (COVID-19) susceptibility. Clin. Infect. Dis. 2021, 73, 328–331. [Google Scholar]
- Ji, Z.; Hu, H.; Qiang, X.; Lin, S.; Pang, B.; Cao, L.; Zhang, L.; Liu, S.; Chen, Z.; Zheng, W.; et al. Traditional Chinese Medicine for COVID-19: A Network Meta-Analysis and Systematic Review. Am. J. Chin. Med. 2022, 50, 883–925. [Google Scholar] [CrossRef]
- Tsai, K.-C.; Huang, Y.-C.; Liaw, C.-C.; Tsai, C.-I.; Chiou, C.-T.; Lin, C.-J.; Wei, W.-C.; Lin, S.J.-S.; Tseng, Y.-H.; Yeh, K.-M. A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study. Biomed. Pharmacother. 2021, 133, 111037. [Google Scholar]
- Basoalto, R.; Damiani, L.F.; Bachmann, M.C.; Fonseca, M.; Barros, M.; Soto, D.; Araos, J.; Jalil, Y.; Dubo, S.; Retamal, J.; et al. Acute lung injury secondary to hydrochloric acid instillation induces small airway hyperresponsiveness. Am. J. Transl. Res. 2021, 13, 12734–12741. [Google Scholar] [PubMed]
- Tavares, A.H.; Colby, J.K.; Levy, B.D.; Abdulnour, R.E. A Model of Self-limited Acute Lung Injury by Unilateral Intra-bronchial Acid Instillation. J. Vis. Exp. 2019, 150, e60024. [Google Scholar] [CrossRef]
- Imai, Y.; Kuba, K.; Rao, S.; Huan, Y.; Guo, F.; Guan, B.; Yang, P.; Sarao, R.; Wada, T.; Leong-Poi, H.; et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005, 436, 112–116. [Google Scholar] [CrossRef] [PubMed]
- Matute-Bello, G.; Downey, G.; Moore, B.B.; Groshong, S.D.; Matthay, M.A.; Slutsky, A.S.; Kuebler, W.M.; Acute Lung Injury in Animals Study, G. An official American Thoracic Society workshop report: Features and measurements of experimental acute lung injury in animals. Am. J. Respir. Cell Mol. Biol. 2011, 44, 725–738. [Google Scholar] [CrossRef]
- Hubner, R.H.; Gitter, W.; El Mokhtari, N.E.; Mathiak, M.; Both, M.; Bolte, H.; Freitag-Wolf, S.; Bewig, B. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques 2008, 44, 507–517. [Google Scholar] [CrossRef]
- Lin, C.I.; Tsai, C.H.; Sun, Y.L.; Hsieh, W.Y.; Lin, Y.C.; Chen, C.Y.; Lin, C.S. Instillation of particulate matter 2.5 induced acute lung injury and attenuated the injury recovery in ACE2 knockout mice. Int. J. Biol. Sci. 2018, 14, 253–265. [Google Scholar] [CrossRef]
- Zheng, J.; Wong, L.R.; Li, K.; Verma, A.K.; Ortiz, M.E.; Wohlford-Lenane, C.; Leidinger, M.R.; Knudson, C.M.; Meyerholz, D.K.; McCray, P.B., Jr.; et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature 2021, 589, 603–607. [Google Scholar] [CrossRef] [PubMed]
- Yinda, C.K.; Port, J.R.; Bushmaker, T.; Offei Owusu, I.; Purushotham, J.N.; Avanzato, V.A.; Fischer, R.J.; Schulz, J.E.; Holbrook, M.G.; Hebner, M.J. K18-hACE2 mice develop respiratory disease resembling severe COVID-19. PLoS Pathog. 2021, 17, e1009195. [Google Scholar]
- McCray, P.B., Jr.; Pewe, L.; Wohlford-Lenane, C.; Hickey, M.; Manzel, L.; Shi, L.; Netland, J.; Jia, H.P.; Halabi, C.; Sigmund, C.D.; et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 2007, 81, 813–821. [Google Scholar] [CrossRef]
- Lin, H.; Liu, Q.; Zhao, L.; Liu, Z.; Cui, H.; Li, P.; Fan, H.; Guo, L. Circulating Pulmonary-Originated Epithelial Biomarkers for Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis. Int. J. Mol. Sci. 2023, 24, 6090. [Google Scholar] [CrossRef]
- Oz, M.; Lorke, D.E. Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury. Biomed. Pharmacother. 2021, 136, 111193. [Google Scholar] [PubMed]
- Delgado-Roche, L.; Mesta, F. Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-CoV) infection. Arch. Med. Res. 2020, 51, 384–387. [Google Scholar] [PubMed]
- Cecchini, R.; Cecchini, A.L. SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression. Med. Hypotheses 2020, 143, 110102. [Google Scholar]
- Wei, J.; Xiong, X.-f.; Lin, Y.-h.; Zheng, B.-x.; Cheng, D.-y. Association between serum interleukin-6 concentrations and chronic obstructive pulmonary disease: A systematic review and meta-analysis. PeerJ 2015, 3, e1199. [Google Scholar]
- Rincon, M.; Irvin, C.G. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int. J. Biol. Sci. 2012, 8, 1281–1290. [Google Scholar] [CrossRef]
- Rabaan, A.A.; Al-Ahmed, S.H.; Muhammad, J.; Khan, A.; Sule, A.A.; Tirupathi, R.; Mutair, A.A.; Alhumaid, S.; Al-Omari, A.; Dhawan, M.; et al. Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm. Vaccines 2021, 9, 436. [Google Scholar] [CrossRef]
- Simoes e Silva, A.C.; Silveira, K.D.; Ferreira, A.J.; Teixeira, M.M. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br. J. Pharmacol. 2013, 169, 477–492. [Google Scholar] [CrossRef]
- Gaddam, R.R.; Chambers, S.; Bhatia, M. ACE and ACE2 in inflammation: A tale of two enzymes. Inflamm. Allergy Drug Targets 2014, 13, 224–234. [Google Scholar] [CrossRef]
- Cantero-Navarro, E.; Fernandez-Fernandez, B.; Ramos, A.M.; Rayego-Mateos, S.; Rodrigues-Diez, R.R.; Sanchez-Nino, M.D.; Sanz, A.B.; Ruiz-Ortega, M.; Ortiz, A. Renin-angiotensin system and inflammation update. Mol. Cell Endocrinol. 2021, 529, 111254. [Google Scholar] [CrossRef]
- Beyerstedt, S.; Casaro, E.B.; Rangel, E.B. COVID-19: Angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur. J. Clin. Microbiol. Infect. Dis. 2021, 40, 905–919. [Google Scholar] [CrossRef] [PubMed]
- Yang, C.W.; Lu, L.C.; Chang, C.C.; Cho, C.C.; Hsieh, W.Y.; Tsai, C.H.; Lin, Y.C.; Lin, C.S. Imbalanced plasma ACE and ACE2 level in the uremic patients with cardiovascular diseases and its change during a single hemodialysis session. Ren. Fail. 2017, 39, 719–728. [Google Scholar] [CrossRef]
- Goodman, R.B.; Pugin, J.; Lee, J.S.; Matthay, M.A. Cytokine-mediated inflammation in acute lung injury. Cytokine Growth Factor Rev. 2003, 14, 523–535. [Google Scholar] [CrossRef]
- Aschner, Y.; Downey, G.P. Transforming Growth Factor-beta: Master Regulator of the Respiratory System in Health and Disease. Am. J. Respir. Cell Mol. Biol. 2016, 54, 647–655. [Google Scholar] [CrossRef] [PubMed]
- Davey, A.; McAuley, D.F.; O’Kane, C.M. Matrix metalloproteinases in acute lung injury: Mediators of injury and drivers of repair. Eur. Respir. J. 2011, 38, 959–970. [Google Scholar] [CrossRef]
- Vandenbroucke, R.E.; Dejonckheere, E.; Libert, C. A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? Eur. Respir. J. 2011, 38, 1200–1214. [Google Scholar] [CrossRef]
- Shenoy, V.; Qi, Y.; Katovich, M.J.; Raizada, M.K. ACE2, a promising therapeutic target for pulmonary hypertension. Curr. Opin. Pharmacol. 2011, 11, 150–155. [Google Scholar] [CrossRef] [PubMed]
- Kuan, T.C.; Chen, M.Y.; Liao, Y.C.; Ko, L.; Hong, Y.H.; Yen, C.Y.; Hsieh, W.Y.; Cheng, K.S.; Wu, C.L.; Lin, C.S. Angiotensin II downregulates ACE2-mediated enhancement of MMP-2 activity in human cardiofibroblasts. Biochem. Cell Biol. 2013, 91, 435–442. [Google Scholar] [CrossRef]
- Iwazu, Y.; Muto, S.; Hirahara, I.; Fujisawa, G.; Takeda, S.-i.; Kusano, E. Matrix metalloproteinase 2 induces epithelial-mesenchymal transition in proximal tubules from the luminal side and progresses fibrosis in mineralocorticoid/salt-induced hypertensive rats. J. Hypertens. 2011, 29, 2440–2453. [Google Scholar] [CrossRef]
- Eldred, J.A.; Hodgkinson, L.M.; Dawes, L.J.; Reddan, J.R.; Edwards, D.R.; Wormstone, I.M. MMP2 activity is critical for TGFβ2-induced matrix contraction—Implications for fibrosis. Investig. Ophthalmol. Vis. Sci. 2012, 53, 4085–4098. [Google Scholar] [CrossRef]
- Yoon, H.K.; Cho, H.Y.; Kleeberger, S.R. Protective role of matrix metalloproteinase-9 in ozone-induced airway inflammation. Environ. Health Perspect. 2007, 115, 1557–1563. [Google Scholar] [CrossRef]
- Carolina, D.A.-M.; Couto, A.E.S.; Campos, L.C.B.; Vasconcelos, T.F.; Michelon-Barbosa, J.; Corsi, C.A.C.; Mestriner, F.; Petroski-Moraes, B.C.; Garbellini-Diab, M.J.; Couto, D.M.S.; et al. MMP-2 and MMP-9 levels in plasma are altered and associated with mortality in COVID-19 patients. Biomed. Pharmacother. 2021, 142, 112067. [Google Scholar] [CrossRef]
- Kassiri, Z.; Zhong, J.; Guo, D.; Basu, R.; Wang, X.; Liu, P.P.; Scholey, J.W.; Penninger, J.M.; Oudit, G.Y. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ. Heart Fail. 2009, 2, 446–455. [Google Scholar] [CrossRef]
- Zhang, Z.; Chen, L.; Zhong, J.; Gao, P.; Oudit, G.Y. ACE2/Ang-(1-7) signaling and vascular remodeling. Sci. China Life Sci. 2014, 57, 802–808. [Google Scholar] [CrossRef]
- Xian, Y.; Zhang, J.; Bian, Z.; Zhou, H.; Zhang, Z.; Lin, Z.; Xu, H. Bioactive natural compounds against human coronaviruses: A review and perspective. Acta Pharm. Sin. B 2020, 10, 1163–1174. [Google Scholar] [CrossRef] [PubMed]
- Zhang, M.M.; Liu, X.M.; He, L. Effect of integrated traditional Chinese and Western medicine on SARS: A review of clinical evidence. World J. Gastroenterol. 2004, 10, 3500–3505. [Google Scholar] [CrossRef]
- McKimm-Breschkin, J.L.; Jiang, S.; Hui, D.S.; Beigel, J.H.; Govorkova, E.A.; Lee, N. Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference. Antivir. Res. 2018, 149, 118–142. [Google Scholar] [CrossRef]
- Huang, Y.F.; Bai, C.; He, F.; Xie, Y.; Zhou, H. Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19). Pharmacol. Res. 2020, 158, 104939. [Google Scholar] [CrossRef]
- Xia, S.; Zhang, Y.; Wang, Y.; Wang, H.; Yang, Y.; Gao, G.F.; Tan, W.; Wu, G.; Xu, M.; Lou, Z. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: A randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect. Dis. 2022, 22, 196–208. [Google Scholar] [CrossRef] [PubMed]
- Tseng, Y.-H.; Lin, S.J.-S.; Hou, S.-M.; Wang, C.-H.; Cheng, S.-P.; Tseng, K.-Y.; Lee, M.-Y.; Lee, S.-M.; Huang, Y.-C.; Lin, C.-J. Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19: A propensity score-matched analysis. Pharmacol. Res. 2022, 184, 106412. [Google Scholar] [CrossRef]
- Cheng, Y.-D.; Lu, C.-C.; Hsu, Y.-M.; Tsai, F.-J.; Bau, D.-T.; Tsai, S.-C.; Cheng, C.-C.; Lin, J.-J.; Huang, Y.-Y.; Juan, Y.-N. In silico and in vitro studies of Taiwan Chingguan Yihau (NRICM101) on TNF-α/IL-1β-induced Human Lung Cells. BioMedicine 2022, 12, 56. [Google Scholar] [CrossRef]
- Singh, S.; Yang, Y.-F. Pharmacological Mechanism of NRICM101 for COVID-19 Treatments by Combined Network Pharmacology and Pharmacodynamics. Int. J. Mol. Sci. 2022, 23, 15385. [Google Scholar] [CrossRef]
Mice | Group | n | PBS | Acid | NRICM101 |
---|---|---|---|---|---|
WT | Control | 5 | + | − | − |
Acid | 5 | − | + | − | |
Acid+TCM | 5 | − | + | + | |
K18-hACE2 TG | Control | 5 | + | − | − |
Acid | 5 | − | + | − | |
Acid+TCM | 5 | − | + | + | |
mACE2 KO | Control | 5 | + | − | − |
Acid | 5 | − | + | − | |
Acid+TCM | 5 | − | + | + |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lin, C.-H.; Chen, Y.-J.; Lin, M.-W.; Chang, H.-J.; Yang, X.-R.; Lin, C.-S. ACE2 and a Traditional Chinese Medicine Formula NRICM101 Could Alleviate the Inflammation and Pathogenic Process of Acute Lung Injury. Medicina 2023, 59, 1554. https://doi.org/10.3390/medicina59091554
Lin C-H, Chen Y-J, Lin M-W, Chang H-J, Yang X-R, Lin C-S. ACE2 and a Traditional Chinese Medicine Formula NRICM101 Could Alleviate the Inflammation and Pathogenic Process of Acute Lung Injury. Medicina. 2023; 59(9):1554. https://doi.org/10.3390/medicina59091554
Chicago/Turabian StyleLin, Cheng-Han, Yi-Ju Chen, Meng-Wei Lin, Ho-Ju Chang, Xin-Rui Yang, and Chih-Sheng Lin. 2023. "ACE2 and a Traditional Chinese Medicine Formula NRICM101 Could Alleviate the Inflammation and Pathogenic Process of Acute Lung Injury" Medicina 59, no. 9: 1554. https://doi.org/10.3390/medicina59091554